Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY

Congress Asset Management Co. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 126.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,239 shares of the biopharmaceutical company’s stock after buying an additional 150,439 shares during the quarter. Congress Asset Management Co. owned approximately 0.20% of Alnylam Pharmaceuticals worth $107,063,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ALNY. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $25,000. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Finally, ORG Partners LLC grew its stake in Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ ALNY opened at $306.66 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The stock’s fifty day simple moving average is $334.13 and its two-hundred day simple moving average is $403.74. The stock has a market capitalization of $40.67 billion, a PE ratio of 179.33 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) earnings per share. The company’s revenue was up 84.9% on a year-over-year basis. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 53,923 shares of company stock valued at $18,072,087. Company insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ALNY shares. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. HC Wainwright restated a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Finally, Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $468.84.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.